Primary results from the Phase II ARASEC trial show that NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared to a matched ADT-alone arm from a historical control in the CHAARTED trial

ARASEC is a multicenter, open-label trial in U.S. patients designed to be complementary to the pivotal Phase III ARANOTE trial

Results are being presented today as a plenary session during the American Urological Association (AUA) Annual Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--

New data from the Phase II ARASEC trial show NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) resulted in a 71% reduction in the risk of progression or death per CHAARTED criteria compared to ADT alone (HR 0.29; 95% CI 0.20–0.40; P